Table 2 Significant predictors of short survival from start of radiotherapy
Parameter | % 30-day mortality | % 35-day mortality | % 40-day mortality | Significance level* |
|---|---|---|---|---|
KPS 30 | 75 | 81 | 81 | < 0.001 (30, 35, 40) |
KPS 40 | 33 | 33 | 33 | |
KPS 50 | 57 | 64 | 79 | |
KPS 60 | 14 | 18 | 22 | |
KPS 70 | 9 | 11 | 14 | |
KPS 80 | 0 | 0 | 2 | |
KPS 90–100 | 0 | 0 | 0 | |
Inpatient | 26 | 30 | 33 | < 0.001 (30, 35, 40) |
Outpatient | 5 | 7 | 9 | |
Weight loss of at least 10% (6 mo) | 28 | 31 | 37 | < 0.001 (30, 35, 40) |
Stable weight | 1 | 1 | 3 | |
Prostate cancer | 7 | 8 | 8 | 0.03, 0.04, 0.05 |
Breast cancer | 4 | 8 | 9 | |
Small cell lung cancer | 9 | 9 | 18 | |
Non-small cell lung cancer | 20 | 21 | 27 | |
Colorectal cancer | 16 | 19 | 19 | |
Bladder cancer | 30 | 30 | 30 | |
Renal cell cancer | 35 | 35 | 41 | |
Other cancer | 8 | 14 | 19 | |
No systemic treatment | 22 | 25 | 28 | 0.004, 0.005, 0.001 |
Systemic treatment last 4 weeks | 7 | 9 | 11 | |
Systemic treatment > 4 weeks before RT | 23 | 26 | 30 | |
Chemotherapy | 15 | 18 | 23 | 0.02, 0.02, 0.01 |
Endocrine therapy | 4 | 5 | 6 | |
Immune checkpoint inhibitor | 11 | 11 | 11 | |
Tyrosine kinase inhibitor | 21 | 21 | 21 | |
Lactate dehydrogenase high | 20 | 21 | 24 | 0.01, 0.05, 0.02 |
Lactate dehydrogenase normal | 8 | 11 | 12 | |
Albumin low | 39 | 44 | 46 | < 0.001 (30, 35, 40) |
Albumin normal | 8 | 10 | 13 | |
Hemoglobin low | 19 | 22 | 26 | < 0.001 (30, 35, 40) |
Hemoglobin normal | 4 | 4 | 5 | |
Leukocytes low | 23 | 23 | 23 | 0.001, 0.001, 0.002 |
Leukocytes normal | 9 | 11 | 14 | |
Leukocytes high | 26 | 30 | 33 | |
Creatinine low | 28 | 31 | 38 | < 0.001 (30, 35, 40) |
Creatinine normal | 6 | 8 | 10 | |
Creatinine high | 25 | 28 | 28 | |
CRP > 90 mg/L | 38 | 44 | 46 | < 0.001 (30, 35, 40) |
CRP 5–90 mg/L | 13 | 15 | 19 | |
CRP normal | 2 | 2 | 4 | |
Brain metastases | 32 | 32 | 36 | 0.008, 0.03, 0.02 |
No brain metastases | 11 | 13 | 16 | |
Liver metastases | 20 | 22 | 25 | 0.04, 0.05, 0.04 |
No liver metastases | 10 | 12 | 15 | |
Adrenal gland metastases | 30 | 35 | 43 | 0.02, 0.01, 0.002 |
No adrenal gland metastases | 11 | 13 | 16 | |
Pleural effusion | 33 | 41 | 44 | 0.002, < 0.001, < 0.001 |
No pleural effusion | 10 | 11 | 14 | |
Disease progression outside RT area | 23 | 27 | 33 | < 0.001 (30, 35, 40) |
No progression outside RT area | 3 ara> | 4 | 5 | |
Opioid analgesics | 20 | 22 | 25 | < 0.001 (30, 35, 40) |
No opioid analgesics | 0 | 1 | 3 | |
Steroid medication | 23 | 27 | 30 | < 0.001 (30, 35, 40) |
No steroid medication | 6 | 7 | 10 | |
Palliative care team involved | 24 | 29 | 31 | < 0.001 (30, 35, 40) |
Palliative care team not involved | 7 | 8 | 11 |